Fluorouracil

證據等級: L5

預測適應症: 10 個

Fluorouracil: From Antineoplastic Chemotherapy to Botryoid-Type Embryonal Rhabdomyosarcoma of the Vagina

One-Sentence Summary

Fluorouracil (5-FU) is a classic fluoropyrimidine antimetabolite widely used as a backbone of cancer chemotherapy regimens for colorectal, gastric, and other solid tumours worldwide. The TxGNN model predicts it may be effective for Botryoid-Type Embryonal Rhabdomyosarcoma of the Vagina, however there are currently 0 clinical trials and 0 publications directly supporting this extremely rare indication.

Quick Overview

Item	Content
Original Indication	No Singapore registration data available
Predicted New Indication	Botryoid-type embryonal rhabdomyosarcoma of the vagina
TxGNN Prediction Score	99.75%
Evidence Level	L5
Singapore Market Status	Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on known pharmacological information, Fluorouracil (5-FU) is a fluoropyrimidine antimetabolite that inhibits thymidylate synthase (TS), thereby blocking DNA synthesis and disrupting the cell cycle of rapidly proliferating tumour cells. Its broad-spectrum cytotoxic activity theoretically extends to any rapidly dividing malignancy.

Botryoid-type embryonal rhabdomyosarcoma of the vagina is an exceptionally rare paediatric soft tissue sarcoma arising from embryonal rhabdomyoblasts in the vaginal wall. Because rhabdomyosarcoma cells are rapidly dividing, the TS-inhibition mechanism of 5-FU theoretically could confer antiproliferative effects. The TxGNN high prediction score likely arises from an indirect knowledge graph path linking "rhabdomyosarcoma → chemotherapy → 5-FU" rather than any disease-specific evidence.

It is critical to note that the established standard-of-care chemotherapy for rhabdomyosarcoma is the VAC regimen (vincristine + actinomycin-D + cyclophosphamide), not 5-FU. No clinical trials or publications exist for this specific anatomic subtype and this drug combination. The high TxGNN score reflects a computational inference, not clinical validation.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Singapore Market Information

Fluorouracil is not registered with the Health Sciences Authority (HSA) of Singapore. No product authorisations are on record for this drug.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Conventional cytotoxic (Fluoropyrimidine antimetabolite class)
Myelosuppression Risk	Moderate — neutropenia and thrombocytopenia reported, particularly with continuous infusion or high-dose bolus schedules; less pronounced than platinum or alkylating agents
Emetogenicity Classification	Low to moderate
Monitoring Items	CBC with differential (before each cycle), liver function tests, renal function, electrolytes; cardiac monitoring for patients with pre-existing cardiac disease (5-FU-associated vasospasm/cardiotoxicity)
Handling Protection	Must be handled according to cytotoxic drug handling regulations — closed-system drug transfer devices (CSTDs) recommended; avoid skin contact and inhalation

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: There is zero direct clinical or preclinical evidence linking Fluorouracil to botryoid-type embryonal rhabdomyosarcoma of the vagina; the TxGNN prediction (L5) reflects a purely computational inference from knowledge graph topology, and the established standard of care for this disease is the VAC regimen, not fluoropyrimidines.

To proceed, the following is needed:

Preclinical in vitro data demonstrating 5-FU cytotoxicity against rhabdomyosarcoma cell lines (e.g., RD, Rh30) to establish any mechanistic basis
Review of existing VAC-refractory rhabdomyosarcoma literature to determine whether any salvage regimens incorporating 5-FU have been explored
Mechanism of action data from DrugBank API (DG002) to support or refute TS-inhibition rationale in the rhabdomyosarcoma context
Singapore HSA package insert or international prescribing information (DG001) to complete the safety profile
Evaluation of higher-ranked indications with actual evidence (e.g., Liver Sarcoma at rank 7, which has 5 clinical trials and 20 publications) as a more actionable repurposing candidate
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.